Clinical trial
Efficacy and Safety of Imatinib in Chordoma
NCT00150072 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00150072 |
|---|---|
| Title | Efficacy and Safety of Imatinib in Chordoma |
| Official title | Phase II Study of Imatinib Mesylate in Chordoma |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chordoma |
| Intervention type | Drug |
| Interventions | imatinib |
| Enrollment | 55 |
| Start date | Oct 1, 2004 |
| Primary completion | Apr 1, 2008 |
| Completion | Apr 1, 2008 |
| First posted | Sep 8, 2005 |
| Last update posted | Feb 23, 2017 |
| Countries | Italy, Switzerland |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: